Denosumab biosimilar(Mabxience)

地舒单抗生物类似药（Mabxience）

Report date: 2026/05/26 20:00:28

Base Information

Drug NameDenosumab biosimilar(Mabxience)
Drug Alias NameDenbrayceIzambyZadenviEnwylmaMB-09
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsGlucocorticoid-induced osteoporosisFractures, BoneHypercalcemia +[9] 
Global Approved IndicationsGlucocorticoid-induced osteoporosisFractures, BoneHypercalcemia +[9] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/06/26
Country/TerritoryBulgariaUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMabxience Sa
China Registration ClassN/A

Develop Information

Active CompaniesMabxience Research SLAmneal Pharmaceuticals LlcZentiva Ks
Inactive CompaniesN/A
Active IndicationsGlucocorticoid-induced osteoporosisFractures, BoneHypercalcemia +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A